Lifecore Biomedical Inc. (LFCR)vsZoetis Inc (ZTS)
LFCR
Lifecore Biomedical Inc.
$4.00
-1.23%
HEALTHCARE · Cap: $151.78M
ZTS
Zoetis Inc
$116.71
+0.67%
HEALTHCARE · Cap: $51.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 7212% more annual revenue ($9.47B vs $129.47M). ZTS leads profitability with a 28.2% profit margin vs -23.8%. ZTS appears more attractively valued with a PEG of 1.87. ZTS earns a higher WallStSmart Score of 64/100 (C+).
LFCR
Avoid30
out of 100
Grade: F
ZTS
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LFCR.
Margin of Safety
-29.1%
Fair Value
$99.69
Current Price
$116.71
$17.02 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Every $100 of equity generates 66 in profit
Strong operational efficiency at 34.7%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 28 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -76.4% — below average capital efficiency
Expensive relative to growth rate
Trading at 14.9x book value
3.0% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : LFCR
LFCR has a balanced fundamental profile.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.2% and operating margin at 34.7%.
Bear Case : LFCR
The primary concerns for LFCR are EPS Growth, Market Cap, PEG Ratio.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.85 is elevated, increasing financial risk.
Key Dynamics to Monitor
LFCR profiles as a turnaround stock while ZTS is a value play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.95 — expect wider price swings.
ZTS is growing revenue faster at 3.0% — sustainability is the question.
ZTS generates stronger free cash flow (732M), providing more financial flexibility.
Bottom Line
ZTS scores higher overall (64/100 vs 30/100), backed by strong 28.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lifecore Biomedical Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa Maria, California.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?